Obsessive Compulsive Disorder

According to the DSM-IV, Obsessive-Compulsive Disorder is characterized by recurrent obsessions or compulsions that are severe enough to be time consuming (Ie., they take more than 1 hour a day) or cause marked distress or significant interference with functioning. At some point during the course of the disorder, the person MAY have recognized the obsessions or compulsions to be excessive or unreasonable. If another Axis I disorder is present, At some point the person has recognized that behaviors are excessive or unrealistic Obsessions and compulsions cause distress, are time consuming, and significantly interfere with functioning. The content of obsessions and compulsions cannot be accounted for by another disorder.

Obsessions are:

Compulsions are:

Treatment

The Institute treats obsessive compulsive disorder using Dr. Edna Foa's Exposure and Response Prevention Therapy as a behavioral protocol, as well as cognitive components through talk therapy and extensive writing exercises. Our program emphasizes the need to identify and target fear structures, to return our patients to their best possible functioning in daily life. Most of our patients have around a 70% improvement, one of the highest success rates in the United States.

Source: Page 456, DSM-IV, Year 2005, American Psychiatric Association

Announcements & Upcoming Events

LACPA 2012 Brown Bag Lecture January 9, 2012 LACPA Office

Dr. Gorbis will be lecturing on the "Comorbidity of OCD and Eating Disorders and its Implication to Treatment" to members of the LA County Psychological Association. She will be addressing the issue of comorbidity of OCD and eating disorders and the implications of each disorders in terms of etiology as well as treatment.

Medical research study of an investigational medicine for patients with OCD who have not responded to treatment with SSRIs

To pre-qualify for this study, patients must be at least 18 yrs. old, have a documented diagnosis of OCD as defined by the DSM-IV-TR, have been taking one of the following SSRIs for at least six weeks prior to screening and at the minimum daily dosage listed: fuvoxamine (Luvox®) 200 mg, fluoxetine (Prozac®) 40 mg, paroxetine (Paxil®) 40 mg, sertraline (Zoloft®) 100 mg. The study is expected to last about 20 weeks. Each patient will receive study medication and study-related medical evaluations at no cost. Reimbursement for travel may also be provided. Please contact us for additional eligibility requirements.

[Admin: Update]